Protein kinase-independent activation of CFTR by phosphatidylinositol phosphates.

EMBO Rep

Max-Planck-Institut für Biophysik, Marie-Curie-Str. 15, D-60439 Frankfurt/Main, Germany.

Published: January 2004

The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel that is expressed in many epithelia and in the heart. Phosphorylation of CFTR by protein kinases is thought to be an absolute prerequisite for the opening of CFTR channels. In addition, nucleoside triphosphates were shown to regulate the opening of phosphorylated CFTR. Here, we report that phosphatidylinositol 4,5-bisphosphate (PIP(2)) activates human CFTR, resulting in ATP responsiveness of PIP(2)-treated CFTR. PIP(2) alone is not sufficient to open CFTR, but ATP opens nonphosphorylated CFTR after application of PIP(2). The effect of PIP(2) is independent of protein kinases, as PIP(2) activates CFTR in the complete absence of Mg. Phosphatidylinositol and phosphatidylinositol monophosphate activate CFTR less efficiently than PIP(2). PIP(2) application to phosphorylated CFTR may inhibit the CFTR chloride current. We suggest that regulation of CFTR by PIP(2) is a previously unrecognized, alternative mechanism to control chloride conductance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1298951PMC
http://dx.doi.org/10.1038/sj.embor.7400034DOI Listing

Publication Analysis

Top Keywords

cftr
14
cftr chloride
8
protein kinases
8
phosphorylated cftr
8
pip2
8
pip2 activates
8
cftr atp
8
cftr pip2
8
pip2 pip2
8
protein kinase-independent
4

Similar Publications

Limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4) is a rare disease that currently has no cure. It is caused by defects in the gene, mainly missense mutations, which cause the impairment of the sarcoglycan complex, membrane fragility, and progressive muscle degeneration. Here, we studied the fate of some β-sarcoglycan (β-SG) missense mutants, confirming that, like α-SG missense mutants, they are targeted for degradation through the ubiquitin-proteasome system.

View Article and Find Full Text PDF

Cystic fibrosis-related diabetes (CFRD) is the most common non-pulmonary comorbidity in people with cystic fibrosis (CF). Current guidelines recommend insulin therapy as the treatment of choice for people with CFRD. In the past, obesity and overweight were uncommon in individuals with CF.

View Article and Find Full Text PDF

Cystic fibrosis (CF)-related central (CNS) and peripheral nervous system (PNS) disorders have not yet been fully described. We report the first case of post-infective neuromuscular hyperexcitability syndrome in a 23-year-old male patient with CF and pulmonary exacerbation. CNS radiological investigations were unremarkable and no autoantibodies were detected.

View Article and Find Full Text PDF

Purpose: The study evaluated the effects of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in people with cystic fibrosis (pwCF) and a clinical history of Aspergillus fumigatus (AF) infection.

Methods: This prospective cohort study included pwCF who initiated ETI therapy and had received antifungal treatment in the preceding five years due to allergic bronchopulmonary aspergillosis (ABPA group) or other AF-related clinical manifestations (AF group). A control group of pwCF with no prior respiratory cultures positive for AF was also included.

View Article and Find Full Text PDF

Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.

Lancet Respir Med

December 2024

Population Policy and Practice Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address:

Article Synopsis
  • Vanzacaftor-tezacaftor-deutivacaftor is a new CFTR modulator showing safety and effectiveness in phase 2 trials for adults with cystic fibrosis, leading to a study evaluating its use in children aged 6-11.
  • This phase 3 trial, called RIDGELINE, involved participants from 33 clinical sites across eight countries, focusing on children with specific CFTR variants and stable health conditions.
  • The study aimed to assess the drug's safety, tolerability, and efficacy over 24 weeks, with primary outcomes evaluated through various health metrics and participant feedback.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!